India Resurgence Fund completed the acquisition of the API and CRAMS business of Ind-Swift for $200m.

India Resurgence Fund, an India-focused distressed and special situations investment platform, completed the acquisition of the active pharmaceutical ingredients and contract research and manufacturing services business of Ind-Swift, a pharmaceutical manufacturing and marketing company, for $200m.